Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Annayya R. Aroor, James R. Sowers, Guanghong Jia, et al.
AJP Heart and Circulatory Physiology (2014) Vol. 307, Iss. 4, pp. H477-H492
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Cross Mark Policy

(2022)
Open Access | Times Cited: 1336
DPP4 in diabetes
Diana Röhrborn
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 387
Cellular mechanisms underlying obesity-induced arterial stiffness
Annayya R. Aroor, Guanghong Jia, James R. Sowers
AJP Regulatory Integrative and Comparative Physiology (2017) Vol. 314, Iss. 3, pp. R387-R398
Open Access | Times Cited: 152
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Francisco Saraiva, Andrei C. Spósito
Cardiovascular Diabetology (2014) Vol. 13, Iss. 1
Open Access | Times Cited: 121
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
Sho‐ichi Yamagishi, Kei Fukami, Takanori Matsui
Cardiovascular Diabetology (2015) Vol. 14, Iss. 1, pp. 2-2
Open Access | Times Cited: 108
Ghrelin Is a Novel Regulator of GLP-1 Secretion
Jeffrey Gagnon, Laurie L. Baggio, Daniel J. Drucker, et al.
Diabetes (2014) Vol. 64, Iss. 5, pp. 1513-1521
Open Access | Times Cited: 103
Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
Katarina Tomović, Jelena Lazarević, Gordana Kocić, et al.
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 404-422
Open Access | Times Cited: 73
Coagulatory Defects in Type-1 and Type-2 Diabetes
Amélie I. S. Sobczak, Alan J. Stewart
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6345-6345
Open Access | Times Cited: 72
Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction
Grazia Esposito, Donato Cappetta, Rosa Russo, et al.
British Journal of Pharmacology (2016) Vol. 174, Iss. 22, pp. 4070-4086
Open Access | Times Cited: 69
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
Annayya R. Aroor, Javad Habibi, Hemanth Kumar Kandikattu, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 66
Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)
Dong-Wei Shao, Zhao Lijie, Jinfeng Sun
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116464-116464
Closed Access | Times Cited: 7
Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate
Dong‐Sung Lee, Eun-Sol Lee, Md. Morshedul Alam, et al.
Metabolism (2015) Vol. 65, Iss. 2, pp. 89-101
Closed Access | Times Cited: 58
Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice
Hotimah Masdan Salim, Daiju Fukuda, Yasutomi Higashikuni, et al.
Vascular Pharmacology (2015) Vol. 79, pp. 16-23
Closed Access | Times Cited: 53
Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors
Marko Anderluh, Gordana Kocić, Katarina Tomović, et al.
Pharmacology & Therapeutics (2016) Vol. 167, pp. 100-107
Closed Access | Times Cited: 53
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung‐Ho Kim, Jung-hwa Yoo, Woo Je Lee, et al.
Diabetes & Metabolism Journal (2016) Vol. 40, Iss. 5, pp. 339-339
Open Access | Times Cited: 52
Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy
Chor Ho Jo, Sua Kim, Joon-Sung Park, et al.
Kidney & Blood Pressure Research (2018) Vol. 43, Iss. 3, pp. 987-999
Open Access | Times Cited: 49
Natural and non-natural antioxidative compounds: potential candidates for treatment of vascular calcification
Chia‐Ter Chao, Hsiang‐Yuan Yeh, You-Tien Tsai, et al.
Cell Death Discovery (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 48
Cytokine Storm Modulation in COVID-19: A Proposed Role for Vitamin D and DPP-4 Inhibitor Combination Therapy (VIDPP-4i)
Marcelo Maia Pinheiro, Andrea Fabbri, Marco Infante
Immunotherapy (2021) Vol. 13, Iss. 9, pp. 753-765
Open Access | Times Cited: 38
Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury
Yuki Tanaka, Shinji Kume, Masami Chin‐Kanasaki, et al.
Biochemical and Biophysical Research Communications (2016) Vol. 470, Iss. 3, pp. 539-545
Closed Access | Times Cited: 44
Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
Camila Manrique, Javad Habibi, Annayya R. Aroor, et al.
Cardiovascular Diabetology (2016) Vol. 15, Iss. 1
Open Access | Times Cited: 42
DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
Jianqiang Zhang, Qiuyue Chen, Jixin Zhong, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 42
Linagliptin Modulation of Inflammation in Chronic Coronary Artery Disease
K.W. Muir, Dwight D. Harris, Christopher Stone, et al.
Journal of Surgical Research (2025) Vol. 309, pp. 146-155
Open Access
Teneligliptin: expectations for its pleiotropic action
Ryuichi Morishita, Hironori Nakagami
Expert Opinion on Pharmacotherapy (2015) Vol. 16, Iss. 3, pp. 417-426
Open Access | Times Cited: 39
A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats
Shinichiro Kimura, Toyoshi Inoguchi, Toshihide Yamasaki, et al.
Metabolism (2015) Vol. 65, Iss. 3, pp. 138-145
Open Access | Times Cited: 33
The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
Annayya R. Aroor, Camila Manrique‐Acevedo, Vincent G. DeMarco
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top